Eqis Capital Management Inc. Has $364,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Eqis Capital Management Inc. increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,967 shares of the company’s stock after buying an additional 1,246 shares during the period. Eqis Capital Management Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $364,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the company. Trust Co increased its position in shares of Teva Pharmaceutical Industries Limited by 71.7% in the fourth quarter. Trust Co now owns 28,569 shares of the company’s stock worth $1,035,000 after buying an additional 11,929 shares during the last quarter. Manning & Napier Advisors LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 15.0% in the first quarter. Manning & Napier Advisors LLC now owns 96,678 shares of the company’s stock worth $3,101,000 after buying an additional 12,645 shares during the last quarter. Chevy Chase Trust Holdings Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 3.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 6,273 shares of the company’s stock worth $201,000 after buying an additional 207 shares during the last quarter. Private Asset Management Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 8.6% in the first quarter. Private Asset Management Inc. now owns 123,075 shares of the company’s stock worth $3,949,000 after buying an additional 9,727 shares during the last quarter. Finally, Park National Corp OH increased its position in shares of Teva Pharmaceutical Industries Limited by 7.5% in the first quarter. Park National Corp OH now owns 18,114 shares of the company’s stock worth $582,000 after buying an additional 1,265 shares during the last quarter. Hedge funds and other institutional investors own 56.19% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 32.47 on Tuesday. Teva Pharmaceutical Industries Limited has a 1-year low of $27.59 and a 1-year high of $55.79. The firm has a market capitalization of $32.99 billion, a PE ratio of 416.28 and a beta of 0.46. The company’s 50-day moving average price is $31.54 and its 200 day moving average price is $32.37.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, May 11th. The company reported $1.06 EPS for the quarter, meeting the consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The company had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.69 billion. During the same period last year, the company posted $1.20 earnings per share. The firm’s revenue was up 17.0% compared to the same quarter last year. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://sportsperspectives.com/2017/07/25/eqis-capital-management-inc-has-364000-stake-in-teva-pharmaceutical-industries-limited-nyseteva.html.

A number of brokerages recently commented on TEVA. Vetr downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 price objective on the stock. in a research report on Tuesday, July 4th. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Maxim Group reiterated an “outperform” rating and set a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, March 29th. Wells Fargo & Company restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. Finally, Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, June 22nd. Fifteen analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $42.88.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply